Pexelizumab
Pexelizumab
Pexelizumab (pronounced as pex-el-i-zu-mab) is a monoclonal antibody designed for the treatment of acute myocardial infarction and coronary artery bypass graft surgery.
Etymology
The term "Pexelizumab" is derived from the generic naming system for monoclonal antibodies, where "-mab" signifies a monoclonal antibody, "zu" indicates humanized, "li" represents the immune system, and "pex" is a unique stem.
Usage
Pexelizumab works by inhibiting the complement system, a part of the immune system that enhances the ability of antibodies and phagocytic cells to clear microbes and damaged cells from an organism, promotes inflammation, and attacks the pathogen's cell membrane. It specifically targets the C5 complement protein, preventing it from splitting into C5a and C5b, thus reducing inflammation and cell damage.
Related Terms
- Monoclonal antibody: A type of immune cell that is identical to the parent cell and can be used to target specific cells or proteins.
- Acute myocardial infarction: Commonly known as a heart attack, it is a serious condition where the blood supply to the heart is suddenly blocked.
- Coronary artery bypass graft: A surgical procedure to improve blood flow to the heart.
- Complement system: A part of the immune system that enhances the ability of antibodies and phagocytic cells to clear microbes and damaged cells from an organism, promotes inflammation, and attacks the pathogen's cell membrane.
External links
- Medical encyclopedia article on Pexelizumab
- Wikipedia's article - Pexelizumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski